Thomas B Casale Selected Research

Omalizumab (Xolair)

1/2022	Impact of body mass index on omalizumab response in adults with moderate-to-severe allergic asthma.
12/2021	Strategies for choosing a biologic for your patient with allergy or asthma.
1/2021	Omalizumab response in patients with asthma by number and type of allergen.
1/2020	Treatment Benefit with Omalizumab in Children by Indicators of Asthma Severity.
9/2019	Impact of omalizumab on patient-reported outcomes in chronic idiopathic urticaria: Results from a randomized study (XTEND-CIU).
1/2019	Omalizumab Effectiveness by Biomarker Status in Patients with Asthma: Evidence From PROSPERO, A Prospective Real-World Study.
1/2019	Omalizumab effectiveness in asthma-COPD overlap: Post hoc analysis of PROSPERO.
1/2018	The XTEND-CIU study: Long-term use of omalizumab in chronic idiopathic urticaria.
1/2018	Omalizumab response in patients with chronic idiopathic urticaria: Insights from the XTEND-CIU study.
1/2018	Baseline asthma burden, comorbidities, and biomarkers in omalizumab-treated patients in PROSPERO.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Thomas B Casale Research Topics

Disease

80	Asthma (Bronchial Asthma) 03/2022 - 03/2002
28	Allergic Rhinitis 01/2021 - 12/2002
23	Hypersensitivity (Allergy) 03/2022 - 06/2002
11	Seasonal Allergic Rhinitis (Hay Fever) 01/2018 - 01/2003
8	Inflammation (Inflammations) 01/2022 - 02/2003
8	Chronic Urticaria 01/2021 - 01/2014
7	Respiratory Hypersensitivity 01/2022 - 09/2010
7	Anaphylaxis (Anaphylactic Shock) 01/2022 - 01/2006
7	Food Hypersensitivity (Food Allergy) 11/2021 - 11/2004
5	Urticaria (Hives) 12/2021 - 01/2015
5	Atopic Dermatitis (Atopic Eczema) 12/2021 - 10/2008
5	Rhinitis 01/2016 - 04/2004
4	Respiratory Tract Diseases (Respiratory Tract Disease) 07/2016 - 09/2004
3	Chronic Obstructive Pulmonary Disease (COPD) 12/2021 - 01/2019
3	Peanut Hypersensitivity (Peanut Allergy) 01/2021 - 11/2018
3	Rhinosinusitis 01/2021 - 09/2009
3	Perennial Allergic Rhinitis 01/2018 - 08/2005
2	Airway Remodeling 01/2022 - 07/2015
2	Nasal Polyps (Nasal Polyp) 12/2021 - 01/2021
2	Eosinophilic Esophagitis 12/2021 - 07/2011
2	Infections 10/2020 - 11/2003
2	Venom Hypersensitivity 09/2013 - 10/2006
2	Rhinorrhea 02/2012 - 05/2005
1	Respiratory Sounds (Crackle) 03/2022
1	Overweight 01/2022
1	COVID-19 01/2021
1	Churg-Strauss Syndrome (Allergic Angiitis) 01/2021
1	Gastroesophageal Reflux (GERD) 01/2020
1	Zika Virus Infection 01/2018
1	Allergic Conjunctivitis (Giant Papillary Conjunctivitis) 01/2017

Drug/Important Bio-Agent (IBA)

25	Omalizumab (Xolair)FDA Link 01/2022 - 12/2003
17	AllergensIBA 03/2022 - 03/2006
16	Immunoglobulin E (IgE)IBA 10/2021 - 04/2004
15	Adrenal Cortex Hormones (Corticosteroids)IBA 01/2022 - 03/2002
11	Biomarkers (Surrogate Marker)IBA 03/2022 - 01/2016
9	anti-IgE antibodiesIBA 01/2020 - 04/2004
7	Biological ProductsIBA 12/2021 - 09/2010
7	Nitric Oxide (Nitrogen Monoxide)FDA Link 10/2021 - 07/2009
7	Tiotropium Bromide (Spiriva)FDA Link 01/2020 - 05/2015
6	TabletsIBA 01/2021 - 01/2011
6	Immunologic Factors (Immunomodulators)IBA 12/2011 - 09/2004
5	Proteins (Proteins, Gene)FDA Link 11/2018 - 11/2003
5	Pharmaceutical PreparationsIBA 01/2018 - 05/2003
5	Interleukin-13IBA 01/2018 - 08/2012
5	Histamine Antagonists (Antihistamines)IBA 05/2005 - 06/2002
4	Epinephrine (Adrenaline)FDA LinkGeneric 01/2022 - 12/2012
4	Monoclonal AntibodiesIBA 01/2021 - 11/2009
4	SteroidsIBA 01/2016 - 03/2002
4	CytokinesIBA 07/2015 - 09/2010
3	GTP-Binding Proteins (G-Protein)IBA 01/2022 - 10/2012
3	Therapeutic UsesIBA 12/2021 - 10/2010
3	Bronchodilator Agents (Bronchodilators)IBA 11/2020 - 12/2002
3	reslizumabIBA 01/2019 - 07/2017
3	Carbon DioxideIBA 01/2018 - 01/2008
3	fexofenadine (Allegra)FDA LinkGeneric 02/2012 - 05/2003
2	Beclomethasone (Beclometasone)FDA Link 01/2022 - 01/2022
2	GlucocorticoidsIBA 01/2022 - 10/2021
2	Interleukin-17 (Interleukin 17)IBA 01/2022 - 01/2018
2	VaccinesIBA 10/2020 - 01/2018
2	Testosterone (Sustanon)FDA Link 10/2020 - 10/2020
2	benralizumabIBA 01/2019 - 01/2018
2	Interleukin-5 (Interleukin 5)IBA 01/2019 - 01/2018
2	Leukotriene Antagonists (Leukotriene Receptor Antagonists)IBA 07/2018 - 05/2005
2	Salmeterol Xinafoate (Serevent)FDA Link 05/2018 - 05/2015
2	InterleukinsIBA 01/2018 - 01/2016
2	Messenger RNA (mRNA)IBA 01/2016 - 10/2012
2	G-Protein-Coupled Receptors (Receptors, G Protein Coupled)IBA 07/2015 - 10/2012
2	Phosphatidylinositols (Phosphatidylinositol)IBA 08/2012 - 09/2010
2	NF-kappa B (NF-kB)IBA 11/2009 - 02/2008
2	Syk KinaseIBA 11/2009 - 02/2008
2	PPAR gammaIBA 11/2009 - 02/2008
2	Transcription Factors (Transcription Factor)IBA 11/2009 - 02/2008
2	Diphenhydramine (Benadryl)FDA LinkGeneric 05/2008 - 05/2003
1	SolutionsIBA 11/2021
1	dupilumabIBA 10/2021
1	trichostatin A (A 300)IBA 01/2021
1	osthol (osthole)IBA 11/2020
1	coumarinIBA 11/2020
1	AndrogensIBA 10/2020
1	SmokeIBA 01/2020
1	mepolizumabIBA 01/2018
1	RNA (Ribonucleic Acid)IBA 01/2018
1	PeriostinIBA 12/2017
1	Environmental Pollutants (Pollutants, Environmental)IBA 04/2017
1	Investigational DrugsIBA 03/2017
1	Muscarinic Receptors (Muscarinic Acetylcholine Receptor)IBA 07/2016
1	Muscarinic AntagonistsIBA 07/2016
1	Acetylcholine (Acetylcholine Chloride)FDA Link 07/2016
1	Neurotransmitter Agents (Neurotransmitter)IBA 07/2016
1	pirfenidoneIBA 01/2016

Therapy/Procedure

43	Therapeutics 01/2022 - 03/2002
17	Immunotherapy 11/2021 - 01/2006
5	Drug Therapy (Chemotherapy) 05/2017 - 05/2005
2	Duration of Therapy 10/2020 - 01/2011
2	Nebulizers and Vaporizers (Inhaler) 01/2020 - 10/2019
2	Biological Therapy 01/2018 - 07/2017
2	Precision Medicine 01/2016 - 01/2016
1	Drug Tapering 01/2022
1	Molecular Targeted Therapy 01/2021
1	Chinese Traditional Medicine (Traditional Chinese Medicine) 11/2020